Johnson & Johnson (NYSE:JNJ - Get Free Report) will likely be posting its quarterly earnings results before the market opens on Wednesday, January 22nd. Analysts expect Johnson & Johnson to post earnings of $1.99 per share and revenue of $22,438,500.00 billion for the quarter. Individual that are interested in participating in the company's earnings conference call can do so using this link.
Johnson & Johnson Stock Performance
NYSE:JNJ traded down $0.74 during trading hours on Monday, reaching $147.03. 10,678,393 shares of the company's stock were exchanged, compared to its average volume of 6,880,262. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $353.99 billion, a price-to-earnings ratio of 21.28, a P/E/G ratio of 2.30 and a beta of 0.51. The company has a 50-day moving average of $148.51 and a 200 day moving average of $156.10.
Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.37%. Johnson & Johnson's dividend payout ratio (DPR) is 71.78%.
Analyst Upgrades and Downgrades
Several analysts have commented on JNJ shares. Guggenheim upped their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the company a "neutral" rating in a research note on Wednesday, November 6th. StockNews.com downgraded Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday. Cantor Fitzgerald reissued an "overweight" rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Citigroup reduced their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a research note on Wednesday, December 11th. Finally, Morgan Stanley increased their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $174.29.
Check Out Our Latest Research Report on Johnson & Johnson
Insider Buying and Selling
In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares of the company's stock, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by insiders.
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
